Adipose derived stem cell transplantation is better than bone marrow mesenchymal stem cell transplantation in treating hindlimb ischemia in mice

• Published in: Biomedical research and therapy Vol. 3; no. 9
• Main Authors: Vu, Ngoc Bich, Phi, Lan Thi, Dao, Thuy Thi-Thanh, Le, Ha Thi-Ngan, Ta, Van Thanh, Pham, Phuc Van
• Format: Journal Article
• Language: English
• Published: Ho Chi Minh City Laboratory of Stem Cell Research and Application 01-10-2016
• Subjects: Biomedical and Life Sciences; Biomedicine; Original Research; Mesenchymal stem cell; adipose derived stem cell; hindlimb ischemia; bone marrow derived stem cell; allograft
• ISSN: 2198-4093; 2198-4093
• DOI: 10.7603/s40730-016-0046-0

Introduction:
Bone marrow derived MSCs (BM-MSCs) and adipose derived MSCs (AD-MSCs) are among the types of stem cells most commonly studied. Our study aims to compare the therapeutic efficacy of allograft AD-MSCs versus BM-MSCs in a mouse model of hindlimb ischemia.
Methods:
AD-MSCs were isolated from belly fat and BM-MSCs were isolated from femur bone marrow. They were used to treat mice with acute hindlimb ischemia. Treatment efficacy was compared among 4 groups: injected with BM-MSCs, injected with AD-MSCs, non-treated and injected with phosphate buffered saline. Mice in the groups were evaluated for the following: necrosis grade of leg, leg edema, blood flow, muscle cell restructure and new blood vessel formation.
Results:
Results showed that AD-MSC transplantation significantly recovered acute limb ischemia, with 76.5% of mice fully recovered, while the ratio was only 48.5% in BM-MSC transplanted group, and 0% in the non-treated and PBS groups. Evaluation of leg edema, blood flow, muscle cell restructure and new blood vessel formation also supported the observation that AD-MSC transplantation was superior over BM-MSC transplantation.
Conclusion:
Therefore, AD-MSCs may serve as the more suitable MSC for hindlimb ischemia treatment and angiogenesis therapy.